A Data Collection Protocol to Evaluate the Real World Usage of the Orthofix AccelStim Device to Treat Fresh Metatarsal Fractures (ASRW)
A Multi-Center Retrospective Data Collection Protocol to Evaluate the Real World Usage of the Orthofix AccelStim Device to Treat Fresh Metatarsal Fractures
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
Illinois
-
Evanston, Illinois, United States, 60208
- Northwestern
-
Mount Prospect, Illinois, United States, 60056
- Endeavor Health
-
-
Maryland
-
Laurel, Maryland, United States, 20707
- Precision Orthopedics
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Fresh metatarsal fracture patient that has been prescribed an Orthofix AccelStim device
- Patient is 18 years or older at the time of treatment
Exclusion Criteria:
-Patient is a prisoner
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
AccelStim (LIPUS)
This group will include subjects where AccelStimStim (LIPUS) is used to treat fresh metatarsal fracture
|
Subjects treated with LIPUS were directed to use the AccelStim device for 20 minutes per day, up to 6 months or until no longer needed.
Other Names:
|
|
Control (no LIPUS device)
This group will include subjects where AccelStimStim (LIPUS) was not used to treat fresh metatarsal fracture
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Healing Status
Time Frame: 3, 6, and 12 month
|
Quantitative and qualitative assessments of clinical and radiographic healing (as available per standard of care)
|
3, 6, and 12 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain (NPRS) (0-100)
Time Frame: Baseline, 3, 6, and 12 month
|
Numerical Pain Rating Scale (NPRS) (0-100, where 100 is maximum pain)
|
Baseline, 3, 6, and 12 month
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- CIP-ASRW-24
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.